Latest News and Press Releases

Kuehn Law investigates HA, ICVX, PXD, HARP mergers, seeks to protect shareholder interests. Shareholders urged to contact the firm.

We are investigating the fairness of the sale of Harpoon Therapeutics to Merck for $23.00 per share in cash.

SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...

Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical...

Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor...

SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented...

SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...

HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million...

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers,...

Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®)...